Covidien Receives CE Mark Approval for EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System

One-Handed Stent Delivery System Offers Controlled Delivery, Greater Accuracy and Ease of Use

LEIPZIG, Germany--()--Covidien, a leading global provider of healthcare products, today announced CE Mark approval for its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System.

The advanced stent delivery system, specifically engineered for optimal control, is designed to allow physicians to consistently place stents in the desired location with accuracy and ease. The product will be rolled out in Western Europe next month.

An alternative to the traditional two-handed approach, the Entrust delivery system is currently the only one-handed delivery system on the market with a triaxial design to offer a 5 F profile that is compatible with a 0.035” guidewire. This unique combination of features is designed for superior performance during stent delivery, even when treating patients with complex conditions. Other features include a diverse range of catheter lengths and a broad stent matrix for greater treatment options.

“This delivery system exceeds my expectations and addresses a true need in the market for better control and accuracy,” said Dr. Arne Schwindt, Senior Vascular Surgeon, St. Franziskus Hospital, Munster, Germany. “With a lower profile, the puncture site is smaller, resulting in less bleeding and other access complications, reduced need for a closure device and faster ambulatory rates. The new 150cm catheter length also allows access to lesions via the brachial artery, which is becoming increasingly necessary for patients with conditions that prevent femoral access.”

With the Entrust delivery system, physicians can deploy all sizes of the Covidien EverFlex stent on a low 5 F profile without reducing the stent’s radial force. The EverFlex stent was shown to be safe and effective in the DURABILITY II clinical study.

“Our Entrust technology takes one-handed delivery to a new level for treating patients with varying conditions,” said Brian Verrier, Vice President and General Manager, Peripheral Vascular, Covidien. “Like many Covidien innovations, the design of the Entrust delivery system is based on extensive physician feedback and procedural observation.”

The EverFlex Self-expanding Peripheral Stent with Entrust Delivery System is being demonstrated here at LINC 2013 (The Leipzig Interventional Course) through January 26. For more information about the system, please join Covidien in Hospitality Suite A9 or at Booth 24.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Contacts

Vascular Therapies
David T. Young, 508-452-1644
Manager, External Communications
david.young@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

Covidien received CE Mark approval for its EverFlex(TM) Self-expanding Peripheral Stent with Entrust(TM) Delivery System. (Photo: Business Wire)

Covidien received CE Mark approval for its EverFlex(TM) Self-expanding Peripheral Stent with Entrust(TM) Delivery System. (Photo: Business Wire)

???news_view.multimedia.download???

???pagination.previous??? ???pagination.next???

Release Summary

Covidien today announced CE Mark approval for its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System.

Sharing

Contacts

Vascular Therapies
David T. Young, 508-452-1644
Manager, External Communications
david.young@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com